[go: up one dir, main page]

MA30345B1 - Formulation d'anticorps monoclonal humain anti-igf-1r - Google Patents

Formulation d'anticorps monoclonal humain anti-igf-1r

Info

Publication number
MA30345B1
MA30345B1 MA31308A MA31308A MA30345B1 MA 30345 B1 MA30345 B1 MA 30345B1 MA 31308 A MA31308 A MA 31308A MA 31308 A MA31308 A MA 31308A MA 30345 B1 MA30345 B1 MA 30345B1
Authority
MA
Morocco
Prior art keywords
igf
monoclonal antibody
human monoclonal
antibody formulation
formulation
Prior art date
Application number
MA31308A
Other languages
English (en)
Inventor
Adelbert Grossmann
Hanns-Christian Mahler
Astrid Pappenberger
Oliver Boris Stauch
Jan Olaf Stracke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA30345B1 publication Critical patent/MA30345B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une formulation d'anticorps monoclonal humain anti-IGF-1R, un procédé pour la préparation et les utilisations de celle-ci.
MA31308A 2006-03-28 2008-10-20 Formulation d'anticorps monoclonal humain anti-igf-1r MA30345B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06111848 2006-03-28

Publications (1)

Publication Number Publication Date
MA30345B1 true MA30345B1 (fr) 2009-04-01

Family

ID=37025222

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31308A MA30345B1 (fr) 2006-03-28 2008-10-20 Formulation d'anticorps monoclonal humain anti-igf-1r

Country Status (18)

Country Link
EP (1) EP1998806A1 (fr)
JP (1) JP2009531371A (fr)
KR (1) KR20080104160A (fr)
CN (1) CN101410137A (fr)
AR (1) AR060130A1 (fr)
AU (1) AU2007229554A1 (fr)
BR (1) BRPI0709229A2 (fr)
CA (1) CA2647111A1 (fr)
CL (1) CL2007000797A1 (fr)
CR (1) CR10295A (fr)
EC (1) ECSP088778A (fr)
IL (1) IL193904A0 (fr)
MA (1) MA30345B1 (fr)
MX (1) MX2008012295A (fr)
NO (1) NO20083895L (fr)
RU (1) RU2008142359A (fr)
TW (1) TW200815029A (fr)
WO (1) WO2007110339A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009006199A (es) * 2006-12-11 2009-06-22 Hoffmann La Roche Formulacion parenteral de anticuerpos abeta.
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
CN101668540A (zh) * 2007-03-22 2010-03-10 英克隆有限责任公司 稳定的抗体制剂
WO2009007272A1 (fr) * 2007-07-10 2009-01-15 F. Hoffmann-La Roche Ag Nouvelle formulation
CA2706403A1 (fr) * 2007-11-29 2009-06-04 F. Hoffmann-La Roche Ag Agregats d'immunoglobulines
MX2010006395A (es) * 2007-12-21 2010-07-01 Hoffmann La Roche Formulacion de anticuerpos.
WO2010069858A1 (fr) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Composition pharmaceutique
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
AU2010338305A1 (en) * 2009-12-29 2012-05-24 F. Hoffmann-La Roche Ag Antibody formulation
WO2011147921A1 (fr) * 2010-05-28 2011-12-01 Novo Nordisk A/S Compositions stables multi-doses comprenant un anticorps et un agent conservateur
KR20190116563A (ko) 2011-03-31 2019-10-14 머크 샤프 앤드 돔 코포레이션 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
CN102363040B (zh) * 2011-10-21 2013-05-01 北京锐瑟科技有限公司 用于粘膜组织的抗微生物肽制剂
RU2687043C2 (ru) 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
ES2746136T3 (es) 2013-04-29 2020-03-04 Hoffmann La Roche Anticuerpos modificados de unión a FcRn humano y procedimientos de uso
CN103505729B (zh) * 2013-05-24 2015-10-28 华北制药集团新药研究开发有限责任公司 一种稳定的狂犬病毒人源抗体组合制剂
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
MX380658B (es) 2014-01-15 2025-03-11 Hoffmann La Roche Variantes de region fc con union mejorada de la proteina a.
US10206878B2 (en) * 2014-05-28 2019-02-19 Nono Inc. Lyophilized formulation of TAT-NR2B9C with acetylation scavenger
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
RU2729416C2 (ru) 2015-06-24 2020-08-06 Ф. Хоффманн-Ля Рош Аг Антитела против трансферринового рецептора, обладающие индивидуализированной аффинностью
RU2731418C2 (ru) * 2015-09-28 2020-09-02 Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
CN106199007B (zh) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 蛋白保护剂
CN119119244A (zh) 2016-08-16 2024-12-13 里珍纳龙药品有限公司 用于对混合物中的个体抗体进行量化的方法
CN119492842A (zh) 2016-10-25 2025-02-21 里珍纳龙药品有限公司 用于色谱数据分析的方法和系统
MX2019013072A (es) 2017-05-02 2019-12-16 Merck Sharp & Dohme Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN118416215A (zh) 2017-09-19 2024-08-02 里珍纳龙药品有限公司 减少粒子形成的方法以及由其形成的组合物
TW202448568A (zh) 2018-07-02 2024-12-16 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
CA3118144A1 (fr) 2018-11-07 2020-05-14 Merck Sharp & Dohme Corp. Co-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
CN114324882B (zh) * 2020-10-12 2022-12-27 广东菲鹏生物有限公司 蛋白稳定剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0999853T3 (da) * 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
DE60141855D1 (de) * 2001-01-05 2010-05-27 Amgen Fremont Inc Antikörper gegen den rezeptor für den insulinähnlichen wachstumsfaktor i
WO2003009817A2 (fr) * 2001-07-25 2003-02-06 Protein Design Labs, Inc. Formulation pharmaceutique lyophilisee stable d'anticorps igg
CA2519113C (fr) * 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Anticorps contre le recepteur du facteur de croissance 1 analogue a l'insuline et utilisations de ceux-ci
RU2332986C2 (ru) * 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
MXPA06001634A (es) * 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.

Also Published As

Publication number Publication date
NO20083895L (no) 2008-10-24
TW200815029A (en) 2008-04-01
CL2007000797A1 (es) 2008-01-25
KR20080104160A (ko) 2008-12-01
CN101410137A (zh) 2009-04-15
AR060130A1 (es) 2008-05-28
MX2008012295A (es) 2008-10-09
EP1998806A1 (fr) 2008-12-10
CR10295A (es) 2008-10-06
AU2007229554A1 (en) 2007-10-04
JP2009531371A (ja) 2009-09-03
CA2647111A1 (fr) 2007-10-04
BRPI0709229A2 (pt) 2011-06-28
WO2007110339A1 (fr) 2007-10-04
ECSP088778A (es) 2008-10-31
RU2008142359A (ru) 2010-05-10
IL193904A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
MA30345B1 (fr) Formulation d'anticorps monoclonal humain anti-igf-1r
MA31984B1 (fr) Formulation d'anticorps
FR23C1029I1 (fr) Compositions d'anticorps anti-ctla-4
SG196835A1 (en) Human anti-b7rp1 neutralizing antibodies
MA50752A (fr) Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation
MA32099B1 (fr) Composition comprenant un anticorps se liant au domaine ii de her2 et variantes acides de celle-ci
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
MA30910B1 (fr) Anticorps et immunoconjugues, et leurs utilisations
BR0316670A (pt) Anticorpos quiméricos e humanizados para integrina (alfa)5ß1 que modulam a angiogênese
UA92505C2 (ru) Композиции на основе антитела против cd3
EA200601670A1 (ru) Конъюгаты гидроксиалкилкрахмала и белка
BR0208338A (pt) Derivados de piridina
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
PT1557462E (pt) Células de indução da aceitação de um transplante de origem monocítica e a sua preparação e utilização
MA33537B1 (fr) Anticorps anti-cdcp1 humanisés
MA32535B1 (fr) Compositions et procédés pour des anticorps ciblant une protéine du complément c5
MA30922B1 (fr) Anticorps d'agonistes de trkb et leurs utilisations
ATE552276T1 (de) Modifizierter anti-cd52-antikörper
MA30042B1 (fr) Composes calcilytiques
BRPI0509184A (pt) composições farmacêuticas
DK1404377T3 (da) Forbedrede chelatorkonjugater
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
EP2000541A4 (fr) Anticorps monoclonal anti-cd20 humanise
TR200103396T2 (tr) Anti-fas antikoru içeren farmasötik terkipler.